相关实验视频

Updated: Jun 27, 2025

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

治疗Pseudomonas aeruginosa细菌病的短期或长期持续时间:系统性审查和元分析

N Ranganath¹, L C Hassett², O M A Saleh¹

¹Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, MN, USA.

The Journal of hospital infection

|April 30, 2024

概括

针对Pseudomonas aeruginosa血流感染 (PSA-BSI) 的短期抗菌疗法似乎与长期治疗一样有效. 这一发现表明,较短的治疗疗程可能是PSA-BSI管理的可行选择,等待进一步的研究.

科学领域:

传染性疾病传染性疾病
临床微生物学临床微生物学
药理学药理学是指药理学的学科.

背景情况:

血流感染 Pseudomonas aeruginosa (PSA-BSI) 与高死亡率有关.
对于PSA-BSI的最佳治疗持续时间仍未确定,长期治疗通常是首选的.
影响治疗持续时间的因素包括感染严重程度,患者复杂性和抗菌素耐药性问题.

研究的目的:

系统地审查和元分析比较PSA-BSI短期与长期抗菌治疗的研究.
评估治疗持续时间对关键临床结果的影响,包括死亡率和感染复发.
为PSA-BSI提供基于证据的见解,了解最佳的管理持续时间.

主要方法:

对头对头比较研究的系统审查和元分析.
在多个数据库 (MEDLINE,Embase,Cochrane,Scopus) 中进行全面的文献搜索.
使用随机效应模型组合风险比率;评估异质性 (I2-指数) 和偏差风险 (ROBINS-I).

主要成果:

在分析中包括了5项涉及1746名患者的研究.
在短期和长期治疗之间,复合结局 (30天死亡率或复发性感染) 没有显著差异 (RR 0.80;95% CI 0.51-1.25)).
30天死亡率和复发/持久感染的个人结局也没有受到治疗持续时间的显著影响.

结论:

短期抗微生物治疗的疗效与PSA-BSI的长期治疗相美.
目前的证据表明,较短的治疗疗程可能足以控制PSA-BSI.
需要进一步进行随机对照试验,以确定PSA-BSI抗微生物治疗的最佳持续时间.

关键词:

抗生素抗生素是一种抗生素.抗微生物药物管理管理细菌血症是什么意思持续时间持续时间伪omonas空气菌伪omonas空气菌

更多相关视频

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

Time-Lapse Epifluorescence Microscopy Imaging of Pseudomonas aeruginosa and Staphylococcus aureus Heterogeneous Phenotypes

Time-Lapse Epifluorescence Microscopy Imaging of Pseudomonas aeruginosa and Staphylococcus aureus Heterogeneous Phenotypes

Published on: February 14, 2025

相关概念视频

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...